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ABSTRACT
Purpose: Large and consistent evidence supports the role of body mass index (BMI) as a prognostic and
predictive indicator in breast cancer. However, there is paucity of data speciﬁcally referred to women
diagnosed at a young age across the different disease settings. We investigated the impact of BMI on
treatment outcomes in 86 breast cancer patients aged 45 y or less treated with neoadjuvant
chemotherapy (CT) followed by surgery.
Methods: Pathologic complete response (pCR) was deﬁned as the eradication of cancer from both breast
and lymph nodes. Overall survival (OS) and disease-free survival (DFS) were calculated using the Kaplan-
Meier product-limit method. Curves were compared by long rank test for signiﬁcance. Potential predictors
of survival were tested in Cox models.
Results: We observed a pCR in 19 patients (22%). Lower values of BMI were more commonly associated with
pCR (p D 0.05). Results from univariate, but not multivariate, models were somewhat supportive of higher
pCR rates in leaner women (p D 0.06). None of the variables impacted DFS. OS was longer in leaner patients
(medians and 95%CI: 74.6 months, 66.2–82.9 and 58.5 months, 49.6–67.4, p D 0.009). Longer OS was also
related to lower T-stage, adjuvant radiotherapy (RT), and non triple negative (TN) subtype (p D 0.046,
p D 0.024, and p D 0.015, respectively). Cox models conﬁrmed the protective role of lower BMI (Hazard
Ratios: 0.30, 95%CI: 0.12–0.71, pD 0.007), non TN subtype and adjuvant RT (p D 0.008 and p D 0.024).
Conclusions: In young breast cancer patients treated with neoadjuvant CT followed by surgery, lower values of
BMI are associated with longer OS. Our data also showed longer OS in association with a non TN molecular
subtype and adjuvant RT. The modiﬁable nature of BMI and aggressive biologic behavior of the disease
diagnosed at a young age encourage further studies to corroborate our ﬁndings.
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Background
Body mass index (BMI) is an anthropometric parameter widely
used for medical purposes. Its applicability both in clinical rou-
tine and research spans across several and heterogeneous areas
including major chronic diseases and common causes of
death.1-5 BMI is by nature an easily assessable indicator and, if
standardized operative procedures are applied at the time of
data collection, a highly reproducible measure.6 Medical oncol-
ogists have ﬁrst relied on BMI to fulﬁll dose deﬁnition needs in
patients treated with chemotherapeutic agents. Since then, the
potential value of this anthropometric factor has signiﬁcantly
evolved until its role as a prognostic and/or predictive determi-
nant has consistently emerged in breast and other cancers.7-8
The growing interest of the cancer research community toward
BMI is further enhanced by its modiﬁable nature and encour-
aging results from trials of life-style modiﬁcations and/or
administration of drugs acting on energy metabolism in breast
cancer patients.9-13
Breast cancer tends to assume a particularly aggressive
behavior in younger patients.14-15 Given the rarity of these
events in the overall population, young patients do not beneﬁt
from speciﬁcally tailored screening initiatives, neither have
they been stably placed within pre-existing breast cancer
screening programs mostly conceived for women aged 50 and
older. This translates into worse outcomes which are compara-
ble to those of older women not participating in the screening
programs.16 The barely sustainable physical, social and lifestyle
challenges faced by young women diagnosed with breast cancer
makes it particularly meaningful investigating factors with a
prognostic and/or predictive role.17
The impact of BMI on treatment outcomes in breast can-
cer has been recently addressed in the pooled analysis of
CONTACT Maddalena Barba maddalena.barba@gmail.com, maddalena.barba@shro.org
* These authors contributed equally to this work.
Supplemental data for this article can be accessed on the publisher’s website.
© 2016 Taylor & Francis Group, LLC
CANCER BIOLOGY & THERAPY
2016, VOL. 17, NO. 5, 470–476
http://dx.doi.org/10.1080/15384047.2016.1156265
data from 8 neoadjuvant trials performed by Fontanella and
colleagues. According to their results, a higher BMI was
associated with a lower rate of complete pathologic response
(pCR) and had a detrimental impact on survival outcomes.18
Subsequently, in a further combined individual patient data
analysis, women aged less than 40 y appeared signiﬁcantly
more likely to achieve pCR following neoadjuvant chemo-
therapy (CT) compared to their older counterpart, particu-
larly if diagnosed with hormone receptor (HR) positive,
human epidermal growth factor receptor 2 negative (HRC/
HER2-), or triple negative (TN) breast cancers.19
Based on these ﬁndings, we investigated whether BMI
impacts treatment outcomes following neoadjuvant chemo-
therapy (CT) in a historic cohort of women aged 45 seeking
clinical and instrumental breast examination.
Patients and methods
Data included in the present analysis are from 86 patients aged
45 years who received pre-operative CT followed by surgery
between October 2007 and August 2013. Most of these women
were part of a larger cohort participating in the initiative called
“Underforty Women Breast Cancer Care,” which was sup-
ported by the Campania Region jointly with the Italian Cancer
League (LILT from the Italian “Lega Italiana per la Lotta
Tumori”).20 The overall initiative was approved by the Institu-
tional Ethical Board of the institutions involved. All patients
released a written consent for participating in the study and
allowing the collection of data and their anonymized use for
scientiﬁc purposes. Records concerning demographics, anthro-
pometrics, pathological and clinical features, therapy adminis-
tered and treatment outcomes were gathered, ﬁled and
analyzed by qualiﬁed research assistants working in strict col-
laboration with the surgeons, oncologists and pathologists from
our team. For all the study patients, medical therapy was estab-
lished and administered in full agreement with the current indi-
cations and recommendations in both the neoadjuvant and
adjuvant phase of treatment. Decisions on breast surgery were
informed by the most updated evidence and oriented by the
disease characteristics and patient individual needs. Adjuvant
radiotherapy was administered to patients having undergone
breast conserving surgery (BCS) and, eventually, to women
treated with mastectomy based on an individual patient evalua-
tion including axillary lymph node involvement, primary
tumor size, margins invasion, grade and age.21-24
Statistical methods
Descriptive statistics were computed for all the variables of
interest. Means and ranges were used for continuous data
while frequencies and percentage values for categorical vari-
ables. Existing differences between medians were evaluated
using the T- Student or One Way Anova test according to
the number (2 or more) of groups compared. Similarly,
depending upon the number and size of groups compared,
we used the Pearson’s Chi-squared test of independence or
Fisher’s exact test (2-tailed) to assess the relationship
between categorical variables.
BMI was computed as weight in kilograms divided by the
square of height in meters (kg/m2) and considered as a categor-
ical variable whose modalities were deﬁned according to a cut
off value of 26, namely, the mean BMI computed at this study
population level. pCR was deﬁned as no invasive residual
tumor in breast and lymph nodes (ypT0/is ypN0) 25 and ana-
lyzed for the entire study population and in subgroups deﬁned
upon BMI, mean age, molecular subtypes,26 type of neoadju-
vant regimen, and surgical approach. Given the study focus,
results from analysis testing age, molecular subtype, and sur-
gery were further stratiﬁed by BMI. We also tested these varia-
bles for association with pCR using univariate logistic
regression analysis. Multivariate models were then built by
including those factors testing signiﬁcant at the univariate anal-
ysis and/or for which evidence of a putative role on the associa-
tion of interest was supported by the available literature.
Overall survival (OS) and disease-free survival (DFS) were
calculated using the Kaplan-Meier product-limit method and
curves were compared by long rank test for signiﬁcance. DFS
was deﬁned as the time from the starting date of pre-surgical
chemotherapy to the date of disease progression or last follow-
up evaluation. OS was calculated as the time from the com-
mencement of pre-operative CT to the date of death from any
cause or last contact. Cox proportional hazards models were
used to test the impact of features related to the patients, dis-
ease and administered treatment on survival outcomes in mul-
tivariate analyses. The variable choice was oriented by the
evidence emerged from univariate analysis and previous stud-
ies. The level of signiﬁcance was set at p<0.05. SPSS software
was used for all statistical evaluations (SPSS version 21.0, SPSS
Inc., Chicago, Illinois, USA).
Results
Main descriptive characteristics of the study participants are
reported in Table 1. Mean age was 38 y and ranged between 20
and 45 y. A BMI value equal to or greater than () 26 was
slightly more common and observed in 46 patients (53.5%).
Luminal B breast cancers were the most commonly represented
subtype [39(45.3)]. At cancer diagnosis, our patients most fre-
quently exhibited a T3-4 and/or N0-1stage [58(67.4) and 48
(55.8), respectively]. The greatest majority of our study partici-
pants underwent a pre-surgical neoadjuvant therapy based on
an anthracycline- and/or taxane-including regimen [79(91,9)].
In about 49%(42 patients) of our study population breast sur-
gery was performed according to a conservative approach.
Adjuvant RT and HT were administered in about 65.0% (56)
and 62.8%(54) of patients. Nineteen (22.0%) patients received
adjuvant trastuzumab. The median follow up was 45.0 months
(range:8.0–90.0).
In Table 2, pCR is described for the overall study population
and in groups differing by disease- and patient-related features
including age, BMI, intrinsic molecular subtypes (IMS) and
treatment administered. Overall, we recorded a pCR in 19
patients over 86, namely, in about 22% of our study population.
Lower BMI values were more often associated with pCR com-
pared to what observed for the heavier counterpart, though at a
not fully signiﬁcant extent (p D 0.05). Stratiﬁcation by BMI did
not signiﬁcantly affect results from descriptive analyses
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(Supplementary Table 1). Results from univariate models were
somewhat supportive of higher pCR rates in women with lower
BMI (p D 0.06). However, this result was not conﬁrmed in
multivariate models (Supplementary Table 2).
None of the variables tested impacted DFS signiﬁcantly
(available upon request). Conversely, OS was affected by
BMI (pD0.009) (Fig. 1). A signiﬁcantly longer OS was also
observed in patients with lower stage at diagnosis (p D
0.046, available upon request), and in women who received
adjuvant RT (72.4 months, 64.6–80.2 and 55.3 months,
43.6–67.0, (p D 0.024) (Fig. 2). A longer OS was also condi-
tioned by IMS (p D 0.015, Fig. 3) and, at some extent, by the
chances of being treated with HT (71.2 months, 63.5–79.0 vs
54.3 months, 43.8–64.8, p D 0.05) (available upon request).
Results from multivariate analysis are shown in Table 3. In
Cox models, the protective role of lower BMI was conﬁrmed
(HR: 0.30, 95%CI: 0.12–0.71, p D 0.007). In addition, women
lived signiﬁcantly longer if diagnosed with a non TN breast
cancer, that is, if the disease was molecularly characterized
as luminal A, B or HER2C (p D 0.008), and if having
received adjuvant RT (p D 0.024).
Discussion
In this observational study, we analyzed data from a moderately
sized cohort including 86 women aged 45 y or less treated with
neoadjvant CT followed by surgery. Our scope was to address
an increasingly debated issue, that is, the impact of BMI on
short- and long-term treatment outcomes. Our study cohort
was essentially characterized by 2 distinctive features, namely,
the young age and neoadjuvant setting. We observed a pCR in
about 22% of our cohort, with a suggestion in support of the
association between favorable outcomes and lower BMI. This
was somewhat conﬁrmed in univariate, but not in multivariate,
analysis. The role of BMI emerged more clearly from survival
analysis, with the inherent data showing a signiﬁcantly pro-
longed OS in women whose BMI fell in the lowest category.
The impact of BMI on OS was conﬁrmed in multivariate analy-
sis, along with the inﬂuence of the molecular characteristics
and adjuvant RT.
To the best of our knowledge, no previous study has
addressed the role of BMI in the neo-adjuvant setting with
a focus on young age at diagnosis. Indeed, 2 groups of col-
leagues have separately worked on the impact of BMI on
neoadjuvant treatment outcomes in breast cancer 18 and on
the outcomes of neoadjuvant chemotherapy in young breast
cancer patients.19 The pCR rate observed in our cohort was
about 22%. This is consistent with what reported by Fonta-
nella and co-authors in their individual data pooled analysis
on BMI and neoadjuvant treatment outcomes, wherein a
pCR rate of 21.3% was observed, i.e., 1,890/8,872.18 Our
results are also consistent with those from the work of Loibl
and colleagues, who focused on young breast cancer
patients and found evidence of an inverse association
between age at diagnosis and pCR rate. When compared
across groups differing by age, the pCR rates were 20.9
(303/1,453), 17.7 (545/3,073) and 13.7% (608/4,423) for
women aged less than 40 years, between 40 and 49 years,
and at least 50 years, respectively.19
Results from our analysis provide some support to the asso-
ciation between lower BMI and higher chances of pCR achieve-
ment. This is in key with what described by Fontanella and co-
authors, who observed a higher pCR rate in normal weight
Table 1. Descriptive characteristics of the study participants (N:86).
Mean (range)
Age (years) 38(20–45)
N(%)
aBMI (Kg/m2) <26 40(46.5)
26 46(53.5)
bIMS Luminal A 13(15.1)
Luminal B 39(45.3)
HER2 positive 19(22.0)
Triple negative 15(17.4)
T Stage T1-2 28(32.6)
T3-4 58(67.4)
N Stage N0-1 48(55.8)
N2-3 38(44.2)
Neoadjvant CT cAnthra. and/or tax. 79(91.9)
Sugery dBCS 42(48.8)
Mastectomy 44(51.2)
Adjuvant CT Anthra. and/or tax
eRT Yes 56(65.1)
fHT Yes 54(62.8)
aBMI: Body mass index. BMI categories were deﬁned upon the mean value com-
puted for this study population, i.e., 26
bIMS (Intrinsic Molecular Subtype): Clinico-pathologic surrogate deﬁnition of intrin-
sic subtypes of breast cancer (26 in the reference list)
cNeoadjuvant CT: Anthra. and/or tax.: Anthracycline-and/or Taxane-based regimen
dBCS: Breast Conservative Surgery
eRT: Adjuvant radiotherapy
f HT: Adjuvant hormone therapy.
Table 2. Pathologic complete response(pCR) in the overall study population and in subgroups deﬁned by participant- and disease-related features (N:19 pCR out of 86
study participants).
N(%) p
pCR 19(22.1)
Age <38 9 (47.4) .52
38 10 (52.6)
aBMI <26 12(63.2) 0.05
26 7(36.8)
bIntrinsic Molecular Subtypes Luminal ALuminal BHER2 positiveTriple negative 2(10.5)9(47.4)3(15.8)5(26.3) .593
T Stage N Stage 1-23-40-12-3 7(36.8)12(63.2)10(52.6)9(47.4) .424.430
Neoadj. CT cAnt.and/orTax. 12(63.2) .200
Other 7(36.8)
aBMI: Body mass index (Kg/m2), BMI categories were deﬁned upon the mean value computed for this study population, i.e., 26
bIMS (Intrinsic Molecular Subtype): Clinico-pathologic surrogate deﬁnition of intrinsic subtypes of breast cancer (Reference 26)
cNeoadjuvant CT: Anthra. and/or tax.: Anthracycline-and/or Taxane-based regimens.
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patients, namely, in women whose BMI was between 18.5 and
25, compared with other BMI groups.18 In our work, BMI
groups were deﬁned based on the mean value computed at the
study population level, namely, 26. This latter cut off is slightly
higher than that suggested by the world health organization
(WHO) to distinguish between normal weight and overweight
patients.27 However, when BMI categories were re-deﬁned
according to this same cut off, i.e. Twenty-ﬁve rather than 26,
the 57.9% (11/19) of pCR still fell in the lowest BMI categories
(p D 0.14).
Figure 1. Overall survival (OS) by subgroups deﬁned upon BMI, i.e., BMI: <26 and BMI26.
Figure 2. Overall survival (OS) by subgroups deﬁned upon intrinsic molecular subtype (IMS).
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Overall survival was signiﬁcantly longer in patients within
the lowest BMI category. The detrimental effect of BMI on OS
in the neoadjuvant setting was also reported by Fontanella and
co-authors. In addition, large and consistent evidence links
poorer survival outcomes to higher BMI values not only in the
neoadjuvant setting but also in the metastatic and adjuvant set-
tings (28-29-30). A number of mechanisms may actually con-
cur to provide a biological rationale for the role of BMI on
treatment outcomes in the neoadjuvant and other breast cancer
settings. In regard to survival outcomes, several and heteroge-
neous determinants may potentially be involved. Hormones,
adipocytokines, and meaditors of inﬂammatory processes such
as cytokines are all related to key aspects of cell survival or apo-
ptosis, migration, and proliferation. Though in premenopausal
women estrogens are mainly of gonadic origin, adipose tissues
represent an adjunctive source of these hormones via aromati-
zation from androgens. Higher levels of insulin are commonly
observed in overweight and obese women and related to poorer
prognosis in breast cancer patients. Possible interactions have
been described between leptin and insulin, and obesity-related
markers of inﬂammation have also been described in associa-
tion with breast cancer outcomes. Further mechanisms could
include obesity-related co-morbidities which may act as contra-
indications to the most effective treatment at the individual
patient level.31-35
Several studies have shown that young breast cancer patients
are more likely to exhibit a TN subtype (36–37). As shown by
Anders and colleagues, in breast cancer arising at a young age,
speciﬁc biologic differences may be subtype dependent.37 In
our cohort, OS was negatively associated with TN breast can-
cer. This ﬁnding replicates what observed by Chen and col-
leagues in 187 chinese breast cancer patients aged less than
40 y old. In Cox models including lymph node status and
molecular subtype, young patients with TN breast cancer
showed signiﬁcantly worse OS compared to other molecular
subgroups (p D 0.048).38
Figure 3. Overall survival (OS) by subgroups deﬁned upon adjuvant radiotherapy (RT).
Table 3. Cox proportional hazards models of factors associated with Overall Survival (N:86).
Hazard Ratios 95%CIa p
BMI2 0.30 0.12-0.71 0.007
IMS3 0.008
I 0.43 0.15-1.21 0.011
II 0.04 0.01-0.35 0.003
III 0.30 0.12-0.75 0.010
T Stage 0.58 0.23-1.46 0.247
RT4 2.41 1.12-5.18 0.024
195%CI: 95% Conﬁdence Interval
2BMI: Body mass index
3IMS: Intrinsic molecular subtype: the reference category is the triple negative (TN) subtype (reference: 26)
4RT: radiotherapy.
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In our case series, women who did not undergo adjuvant RT
showed a signiﬁcant disadvantage in terms of OS. According to
the results from descriptive analysis, 56 women (65.1%)
received RT. Among them, 42 (48.8%) had previously been
treated with BCS, while only 14 (31.8%) of those having
undergone mastectomy received adjuvant RT. Recently, the
administration of postmastectomy radiotherapy (PMRT) has
increasingly attracted the researchers’ attention. However, we
still lack data from randomized trials which may clearly orient
toward the delivery or omission of PMRT in patients who had
been treated with neoadjuvant chemotherapy, which is now an
progressively more common approach. Neither are the avail-
able data speciﬁcally referred to women diagnosed with breast
cancer at a young age.39
Our study has limitations. In ﬁrst place, the observational nature
of the study design makes per se our research more prone to con-
founding and bias compared to randomized clinical trials. How-
ever, thus far, the association of interest has not been addressed
using data from trials. In addition, evidence from a real world pop-
ulationmay fairly suit the clinicians’ needs and integrate knowledge
from future randomized studies. Indeed, due to the strict selection
criteria applied at the time of enrollment, patients from trials may
signiﬁcantly differ from patients from the clinical practice. This
fuels doubts concerning the external validity of the results from
randomized trials and their applicability to a deﬁnable group of
patients in routine practice.40
Our study also has some important strengths. In ﬁrst place, nov-
elty of ﬁndings should be considered. We observed ﬁrst time evi-
dence on the role of BMI, an increasingly used anthropometric
indicator of general obesity, on treatment outcomes in a well char-
acterized cohort of womenwith an indication to neoadjuvant treat-
ment due to breast cancer diagnosed at a young age. Similarly, to
the best of our knowledge, this is the very ﬁrst source of data con-
cerning PMRT in young women having undergone neoadjuvant
systemic treatment. In addition, when considering the rarity of the
condition,41 our series size appears only limitedly restricted and
quite well characterized concerning patients’molecular and clinical
features.
In summary, we carried out an observational study
focused on the role of BMI on the short- and long-term out-
comes of 86 women aged 45 or younger who received neoad-
juvant CT followed by surgery. We found borderline
evidence of higher pCR rates in women within the lowest
BMI category compared to their heavier counterpart. The
evidence emerged from survival analysis of OS was more
robust, with lower values of BMI being associated with sig-
niﬁcantly longer OS. Results from the univariate were con-
ﬁrmed in Cox models. These latter were also conﬁrmative
for more favorable survival outcomes (OS) in patients with
non TN breast cancer and in women who have received
adjuvant RT. It is notable that every social group is vulnera-
ble to the familial, health and economic burden of cancer.
However, current evidence indicates that physical and emo-
tional distress are signiﬁcantly ampliﬁed in patients diag-
nosed at a young age.42 In this view, further evidence
collected throughout ad hoc, prospective studies is urgently
needed to conﬁrm our ﬁndings and eventually explore inter-
ventions targeting BMI for their impact on treatment out-
comes in breast cancer patients diagnosed at a young age.
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